| Cardiac gene therapy: Recent advances and future directions D Mason, YZ Chen, HV Krishnan, S Sant Journal of Controlled Release 215, 101-111, 2015 | 37 | 2015 |
| Controlled three-dimensional tumor microenvironments recapitulate phenotypic features and differential drug response in early vs advanced stage breast cancer M Singh, H Venkata Krishnan, S Ranganathan, B Kiesel, JH Beumer, ... ACS Biomaterials Science & Engineering 4 (2), 421-431, 2018 | 17 | 2018 |
| Circular RNA platform- Long-lived, Robust and Tissue-Specific Therapeutics C Cifuentes-Rojas, S Schwartz, S Amarnath, D Harnett, H Krishnan, ... RNA Society -Annual Meeting, 2023 | | 2023 |
| Development of assays to assess the role of autophagy in neurodegenerative diseases H Venkata Krishnan,J St.Martin, V Yu, S Shah Society for Laboratory Automation and Screening, 2019 | | 2019 |
| ENGINEERED IN VITRO BREAST CANCER MODELS SHOW PHENOTYPIC DIFFERENTIATION CHARACTERISTICS OF EARLY VS. LATE-STAGE DISEASE H Venkata Krishnan University of Pittsburgh, 2016 | | 2016 |
| Affibodies: The next generation affinity proteins. H Venkata Krishnan,P Desai, V Patravale PharmaBiz, 2014 | | 2014 |
| Folic acid conjugated amine functionalized cerium oxide nanoparticle for cancer targeted gene therapy K Sarkar, HV Krishnan, GV Kumar, KS Babu, V Sant, S Sant | | |
| Free radical modulating nanoparticles induce innate immune response. A Patel, J Kosanovich, S Balmuri, H Krishnan, K Empey, S Sant | | |
